New in-house test offers latest advancement in diagnosing canine Lyme disease

IDEXX Laboratories, Inc. announces the release of a new test that willaid veterinarians in the treatment of Lyme disease in dogs. The IDEXX LymeC6 Quantitative Antibody Test allows veterinarians to quantify C6 antibodyconcentration in Lyme-positive dogs, monitor changes in antibody concentrationafter treatment, and gauge the effectiveness of treatment, the company says.The test will be available in November and is offered exclusively at IDEXXReference Laboratories. "This test marks an exciting and revolutionaryadvance in identifying and controlling canine Lyme disease," says TerriWheeler, DVM, of IDEXX. The IDEXX Lyme C6 Quantitative Antibody Test isa natural next step after a positive Lyme result on the IDEXX SNAP®3Dx Test. The combination of the in-clinic and reference laboratory diagnosticsmakes it possible for veterinarians to inexpensively screen all dogs duringroutine annual exams, measure the level of C6 Lyme antibody and monitorthe effectiveness of antibiotic treatment. Changes in antibody concentrationsallow veterinarians to monitor the effectiveness of antibiotic treatmentin both symptomatic and asymptomatic dogs.

For fastest response call (888) 433-9987 or visit the Web site at